Narayana Hrudayalaya Ltd.

rs,

ecretary Listing Department BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code – 539551 Dear Sir/Madam, To, The Secretary Listing

99%

uccessfully performed Stenting of coeliac artery for Descending Aortic, SMA, RRA, CIA stenosis with 99% block of coeliac artery Operational: ▪ NICS - installation of 2 New Cath Labs ▪ DNSH – radiation

INR 12,334

4 Key Highlights – Q1 FY24 ….(2/2) Financial Performance ▪ Consolidated operating revenues of INR 12,334 mn in Q1 FY24, an increase of 19.4% YoY and 1.0% QoQ ▪ Consolidated EBITDA of INR 2,858(1) mn in Q1

19.4%

nancial Performance ▪ Consolidated operating revenues of INR 12,334 mn in Q1 FY24, an increase of 19.4% YoY and 1.0% QoQ ▪ Consolidated EBITDA of INR 2,858(1) mn in Q1 FY24 translating into EBITDA margi

1.0%

mance ▪ Consolidated operating revenues of INR 12,334 mn in Q1 FY24, an increase of 19.4% YoY and 1.0% QoQ ▪ Consolidated EBITDA of INR 2,858(1) mn in Q1 FY24 translating into EBITDA margin of 23.2% an

INR 2,858

venues of INR 12,334 mn in Q1 FY24, an increase of 19.4% YoY and 1.0% QoQ ▪ Consolidated EBITDA of INR 2,858(1) mn in Q1 FY24 translating into EBITDA margin of 23.2% and consolidated PAT of INR 1,840(2) mn

23.2%

and 1.0% QoQ ▪ Consolidated EBITDA of INR 2,858(1) mn in Q1 FY24 translating into EBITDA margin of 23.2% and consolidated PAT of INR 1,840(2) mn at a PAT margin of 14.9% ▪ Consolidated Total Borrowings

INR 1,840

TDA of INR 2,858(1) mn in Q1 FY24 translating into EBITDA margin of 23.2% and consolidated PAT of INR 1,840(2) mn at a PAT margin of 14.9% ▪ Consolidated Total Borrowings less Cash, Bank Balance and Current

14.9%

ranslating into EBITDA margin of 23.2% and consolidated PAT of INR 1,840(2) mn at a PAT margin of 14.9% ▪ Consolidated Total Borrowings less Cash, Bank Balance and Current Investments was INR 188 mn as

INR 188

argin of 14.9% ▪ Consolidated Total Borrowings less Cash, Bank Balance and Current Investments was INR 188 mn as on 30th June, 2023 i.e. net debt to equity ratio of 0.01 (Out of which, debt worth US$ 43 mn

INR 135

s per the accounting treatment for leases per IND AS 116 effective 1st April 2019 which resulted in INR 135 mn increase in EBITDA for Q1 FY24 (2) As per the accounting treatment for leases per IND AS 116 eff

INR 0.5

s per the accounting treatment for leases per IND AS 116 effective 1st April 2019 which resulted in INR 0.5 mn decrease in PAT for Q1 FY24 5 Revenue Mix – India (Q1 FY24) Operating Revenues Business Mix(

Operational

1

Operational

▪ NICS - installation of 2 New Cath Labs ▪ DNSH – radiation Oncology Upgradation to Elekta Synergy Versa HD ▪ NH Jaipur - successfully started the Radiation Oncology Services in May 2023; over 70 patients have been already registered, Also installed cath lab with Interventional radiology capability “GE Azurion 7 M20” 4 Key Highlights – Q1 FY24 ….(2/2) Financial Performance ▪ Consolidated operating revenues of INR 12,334 mn in Q1 FY24, an increase of 19.4% YoY and 1.0% QoQ ▪ Consolidated EBITDA of INR 2,858(1) mn in Q1 FY24 translating into EBITDA margin of 23.2% and consolidated PAT of INR 1,840(2) mn at a PAT margin of 14.9% ▪ Consolidated Total Borrowings less Cash, Bank Balance and Current Investments was INR 188 mn as on 30th June, 2023 i.e. net debt to equity ratio of 0.01 (Out of which, debt worth US$ 43 mn is foreign currency denominated) (1) As per the accounting treatment for leases per IND AS 116 effective 1st April 2019 which resulted in INR 135 mn increase in EBITDA for Q1